A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Related Clinical Trial
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Official Title

A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Brief Summary

      The purpose of the study is to determine the safety and tolerability of escalating doses of
      ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on
      circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A
      (conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9
      escalating dose levels with 6 participants per dose level.
    

Detailed Description

      Healthy volunteers and AATD patients will be randomized to receive a single intravenous
      injection of either ARC-AAT or Placebo in double-blind fashion. Up to thirteen cohorts (6
      participants per cohort) will be enrolled. Participants in all cohorts will be confined to
      the clinical facility beginning on Day -1 with discharge on Day 2. Escalation to the next
      dose level will proceed until a participant experiences a dose-limiting toxicity (DLT) or
      there is achievement of pre-determined threshold reductions in AAT levels. Dosing in
      participants with AATD will commence based on pre-determined threshold reductions in AAT
      levels for healthy volunteers. For each participant, the duration of the study clinic visits
      is up to 11 weeks, from Screening to the End-of-Study examination. However, including a Day
      90 Follow-Up telephone call, the maximum study duration is approximately 20 weeks.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs

Secondary Outcome

 Number of Participants With AAT Reduction > 30% From Baseline (First Occurrence)

Condition

Alpha-1 Antitrypsin Deficiency

Intervention

ARC-AAT Injection

Study Arms / Comparison Groups

 Part A: 0.38 mg/kg
Description:  Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

65

Start Date

February 2015

Completion Date

November 2016

Primary Completion Date

November 2016

Eligibility Criteria

        Inclusion Criteria:

        (Part A - Healthy Volunteers)

          -  Male or female healthy volunteers 18-50 years of age

          -  Written informed consent

          -  Body mass index between 18.0 and 28.0 kg/m2

          -  12-lead electrocardiogram (ECG) at Screening and pre-dose assessment with no
             clinically significant abnormalities

          -  Non-pregnant/non-nursing females

          -  Non-smoker for at least one year with current non-smoking status confirmed by urine
             cotinine

          -  Normal lung function (or not clinically significant per investigator assessment) based
             on spirometry and diffusion capacity of lung for carbon monoxide (DLCO) according to
             American Thoracic Society (ATS) - European Respiratory Society (ERS) criteria

          -  Highly effective, double barrier contraception (both male and female partners) during
             the study and for 3 months following the dose of ARC-AAT

          -  Willing and able to comply with all study assessments and adhere to protocol schedule

          -  Suitable venous access for blood sampling

          -  No abnormal finding of clinical relevance at screening

          -  Normal AAT level

        (Part B-Patients) - As for Part A with the following exceptions:

          -  Male or female patients 18-70 years of age

          -  Confirmed diagnosis of homozygous alpha 1-protease inhibitor deficiency (PiZZ
             genotype) not receiving alpha-1 antitrypsin augmentation therapy for more than 4 weeks

          -  BMI between 18.0 and 35.0 kg/m2

          -  Non-smoker for at least three years with current non-smoking status confirmed by urine
             cotinine

        Exclusion Criteria:

        (Part A-Healthy Volunteers)

          -  Current regular smoker of cigarettes or cigars or was a regular smoker over the past 1
             year

          -  Recent (within last 6 weeks) transfusion of fresh frozen plasma, platelets, or packed
             red blood cells, or anticipated need for transfusion during study

          -  Acute signs of hepatitis/other infection within 4 weeks of screening and/or baseline

          -  Concurrent anticoagulants

          -  Use of dietary and/or herbal supplements that can interfere with liver metabolism
             within 7 days of screening

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 14 days
             prior to study treatment

          -  Depot injection/implant of any drug other than birth control within 3 months prior to
             study treatment

          -  Diagnosis of diabetes mellitus or history of glucose intolerance

          -  History of poorly controlled autoimmune disease or any history of autoimmune hepatitis

          -  Human immunodeficiency virus (HIV) infection

          -  Seropositive for hepatitis B virus (HBV) or hepatitis C virus (HCV), and/or history of
             delta virus hepatitis

          -  Uncontrolled hypertension (blood pressure > 150/100 mmHg)

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome or unexplained sudden cardiac death

          -  Symptomatic heart failure (per New York Heart Association [NYHA] guidelines)

          -  Unstable angina, myocardial infarction, severe cardiovascular disease, transient
             ischemic attack (TIA) or cerebrovascular accident (CVA) within past 6 months

          -  History of malignancy within last 5 years except adequately treated basal cell
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical
             cancer.

          -  History of major surgery within 3 months of screening

          -  Regular use of alcohol within 1 month prior to screening (i.e., more than fourteen
             units of alcohol per week)

          -  Evidence of acute inflammation, sepsis or hemolysis or clinical evidence of lower
             respiratory tract infection

          -  Diagnosis of significant psychiatric disorder

          -  Use of illicit drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year
             prior to screening or positive urine drug screen

          -  History of allergy or hypersensitivity reaction to bee venom

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Clinically significant history/presence of any gastrointestinal pathology, unresolved
             gastrointestinal symptoms, liver or kidney disease

          -  Other conditions known to interfere with the absorption, distribution, metabolism, or
             excretion of drugs

          -  Any clinically significant history/presence of poorly controlled neurological,
             endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric,
             metabolic or other uncontrolled systemic disease

          -  Blood donation (500 mL) within 7 days prior to study treatment

          -  History of fever within 2 weeks of screening

          -  Concomitant medical/psychiatric condition or social situation that would affect
             compliance or result in additional safety risk

          -  Excessive exercise/physical activity within 3 days of screening or enrollment or
             planned during the study

          -  History of thromboembolic disease, stroke within 6 months of baseline, and/or
             concurrent anticoagulant medication(s)

        (Part B-Patients) - As for Part A with the following exceptions:

          -  History of major surgery within 2 months of Screening

          -  Forced expiratory volume at one second (FEV1) at baseline < 60%

          -  AATD patients with liver elastography score > 11 at Screening
      

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT02363946

Organization ID

ARCAAT-1001

Secondary IDs

U1111-1171-0247

Responsible Party

Sponsor

Study Sponsor

Arrowhead Pharmaceuticals


Study Sponsor

, , 


Verification Date

October 2017